

<b>Policy Name:</b>	<b>Synagis (palivizumab)</b>	<b>Policy#:</b>	<b>2325P</b>
---------------------	------------------------------	-----------------	--------------

## Purpose of the Policy

The purpose of this policy is to define the criteria for coverage of Synagis.

## Statement of the Policy

Health Alliance Medical Plans will approve the use of Synagis under the specialty medical benefit when the following criteria have been met

## Criteria

### 1. Coverage Criteria for diagnosis of Congenital Airway Abnormality or Neuromuscular Condition

- 1.1 Documentation of nerves and muscular disorder or congenital abnormality that impairs the ability to cough up mucus from the upper lungs because of ineffective cough
- 1.2 Age 12 months or younger

### 2. Coverage Criteria for diagnosis of Congenital Heart Disease (CHD)

- 2.1 Documentation of CHD hemodynamically significant
- 2.2 Age 12 months or younger

### 3. Coverage Criteria for diagnosis of Chronic Lung Disease (CLD)

- 3.1 Age 24 months or younger
- 3.2 Documentation that patient has received medical treatment for CLD in the 6 months prior to RSV season (medical treatment may include oxygen, bronchodilators, diuretics, or chronic corticosteroids)

### 4. Coverage Criteria for diagnosis of Prematurity

- 4.1 Gestational age of 28 weeks 6 days
- 4.2 Chronological age at the start of RSV season of < 12 months

### 5. Exclusion Criteria

- 5.1 Patients who were already vaccinated against RSV with Beyfortus are not recommended to receive Synagis as well

### 6. Approval Period

- 6.1 5 doses over 6 months during RSV season

## CPT Codes

--	--

## HCPCS Codes

90378	Respiratory syncytial virus, monoclonal antibody, recombinant, for intramuscular use, 50 mg
-------	---

## References

1. Synagis (palivizumab) [prescribing information]. Waltham, MA: Sobi Inc; November 2021.
2. American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. *Pediatrics* 2014; 134:415. (Reaffirmed in 2019).
3. Caserta MT, O'Leary ST, Munoz FM, Ralston SL; COMMITTEE ON INFECTIOUS DISEASES. Palivizumab Prophylaxis in Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection. *Pediatrics*. 2023 Jul 1;152(1):e2023061803.
4. Jones JM, Fleming-Dutra KE, Prill MM, et al. Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023. *MMWR Morb Mortal Wkly Rep* 2023;72:920–925.

**Created Date:** 09/01/13

**Effective Date:** 07/01/24

**Posted to Website:** 01/01/22

**Revision Date:** 06/05/24

#### DISCLAIMER

This Medical Policy has been developed as a guide for determining medical necessity. The process of medical necessity review also entails review of the most recent literature and physician review. Medical Policy is not intended to dictate to providers how to practice medicine. Providers are expected to exercise their medical judgment in providing the most appropriate care. Health Alliance encourages input from providers when developing and implementing medical policies. Benefit determinations are based on applicable contract language in the member's Policy/ Subscription Certificate/ Summary Plan Description. This Medical Policy does not guarantee coverage. There may be a delay between the revision of this policy and the posting on the web. Please contact the Health Alliance Customer Service Department at 1-800-851-3379 for verification of coverage.